{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-001209","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.675281+00:00","generated_at":"2026-06-10T21:37:27.819140+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Lipella presents Phase 2a results for LP-10 at H.C. Wainwright conference","bullets":["Presented at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11, 2023.","Provided update on product pipeline and Phase 2a clinical trial results for drug candidate LP-10.","Presentation materials posted on company website at lipella.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-001209","json":"https://secwatch.observer/filing/0001753926-23-001209.json","markdown":"https://secwatch.observer/filing/0001753926-23-001209.md","text":"https://secwatch.observer/filing/0001753926-23-001209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623001209/0001753926-23-001209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623001209/g083745_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:37:27.819140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}